Fig. 6: NRG1 and PDGFC promote PTX resistance in BC in vivo.

A Schematic diagram of the mouse BC xenograft model established using MDA-MB-231 cells. PTX (15 mg/kg, intraperitoneally, every three days) and recombinant NRG1 protein (5 μg/kg, intratumorally, twice a week) were administered starting on day 11 post-tumor implantation. B Representative images of excised tumors from the mice (n = 6). C Tumor volumes were measured every five days, and mice were sacrificed on day 30 for analysis (n = 6). D Quantification of the excised tumor weights (n = 6). E MDA-MB-231 cells and HFL1 cells were co-injected at a 1:1 ratio into the subcutaneous tissue of nude mice to establish a BC model. PTX (15 mg/kg, intraperitoneally, every three days) and recombinant PDGFC protein (5 μg/kg, intratumorally, twice a week) were administered starting on day 16 post-tumor implantation. F Representative images of excised tumors (n = 6). G Quantification of tumor volume changes in mice (n = 6). H Quantification of excised tumor weights (n = 6). Data are expressed as the mean ± S.D. for all panels: ^##P < 0.01, ***^{, ###}P < 0.001.